Caxton Associates LP Jounce Therapeutics, Inc. Transaction History

Caxton Associates LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.73 - $4.92 $101,951 - $183,737	37,345 New	37,345 $87,000
Q4 2020 Feb 16, 2021	SELL	$6.37 - $10.33 $263,794 - $427,785	-41,412 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.58 - $10.95 $189,666 - $453,461	41,412 New	41,412 $338,000
Q1 2020 May 15, 2020	SELL	$2.91 - $8.7 $163,044 - $487,452	-56,029 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $157,441 - $516,027	56,029 New	56,029 $489,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.